Testing HR+ / HER2-patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)

被引：0
|
作者：
Boutis, A. [1 ]
Nikolaou, M. [1 ]
Ardavanis, A. [1 ]
Tolis, C. [1 ]
Loga, K. [1 ]
Korantzis, I. [1 ]
Koumarianou, A. [1 ]
Christopoulou, A. N. [1 ]
Papatsimpas, G. [1 ]
Bokas, A. [1 ]
Pliarchopoulou, K. [1 ]
Kampletsas, E. [1 ]
Kesisis, G. [1 ]
Biziota, E. [1 ]
Psianou, K. [1 ]
Karageorgopoulou, S. [1 ]
Sogka, E. A. [1 ]
Tsoukalas, N. G. [1 ]
Chatzifoti, N. [1 ]
Saridaki-Zoras, Z. [1 ]
机构：
[1] Hellenic Soc Med Oncol, HeSMO, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439P
引用
收藏
页码：S366 / S366
页数：1
相关论文
共 50 条
  • [31] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [32] Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience
    Caldart, A.
    Fiorio, E.
    Zanelli, S.
    Biondani, P.
    Parolin, V.
    Pellini, F.
    Montemezzi, S.
    Nottegar, A.
    Calio, A.
    Zampiva, I.
    Merler, S.
    Mongillo, M.
    Avesani, B.
    Borghesani, G.
    Giontella, E.
    Scarpa, A.
    Milella, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S38 - S39
  • [33] Incidence and outcomes among patients with HR+/HER2-metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review
    Dempsey, Naomi
    Chamorro, Yolcar
    Tolman, Dana
    Sandoval-Leon, Ana Cristina
    Drusbosky, Leylah
    Lewis, Courtney
    Ahluwalia, Manmeet Singh
    Mahtani, Reshma L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Fusco, Nicola
    Malapelle, Umberto
    Fassan, Matteo
    Marchio, Caterina
    Buglioni, Simonetta
    Zupo, Simonetta
    Criscitiello, Carmen
    Vigneri, Paolo
    Dei Tos, Angelo Paolo
    Maiorano, Eugenio
    Viale, Giuseppe
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] The prevalence of PIK3CA mutations in HR1/HER2-metastatic breast cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)
    Wan, K.
    Wang, Y. A.
    Kaper, M.
    Fritzemeier, M.
    Babbar, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 95 - 95
  • [36] HER2, EGFR, PIK3CA mutations in HER2+metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
    Gori, S.
    Ludovini, V.
    Colozza, M.
    Pistola, L.
    Tofanetti, F. R.
    Flacco, A.
    Foglietta, J.
    Minenza, E.
    Stocchi, L.
    De Angelis, V.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Frequency of PIK3CA Mutations in Chinese HER2+Metastatic Breast Cancer Patients and Association with Clinical Benefit to Lapatinib and Capecitabine Treatment.
    Xu, B.
    Zefei, J.
    Chua, D.
    Shao, Z.
    Luo, R.
    Wang, X.
    Yuan, P.
    Newstat, B.
    Liu, Y.
    Gagnon, R.
    Chi, H.
    Martin, A-M
    Stein, S.
    Wang, L.
    CANCER RESEARCH, 2009, 69 (24) : 583S - 583S
  • [38] Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer
    Gasch, Christin
    Oldopp, Theresa
    Mauermann, Oliver
    Gorges, Tobias M.
    Andreas, Antje
    Coith, Cornelia
    Mueller, Volkmar
    Fehm, Tanja
    Janni, Wolfgang
    Pantel, Klaus
    Riethdorf, Sabine
    MOLECULAR ONCOLOGY, 2016, 10 (08): : 1330 - 1343
  • [39] ESMO 2020: New Data on Alpelisib (Piqray®) on Overall Survival in Patients with HR+/HER2-advanced Breast Cancer with PIK3CA-Mutation
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 67 - 67
  • [40] Characteristics of HR+/HER2-patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
    Alvarez, Isabel
    Guerrero-Zotano, Angel
    Lopez-Tarruella, Sara
    Martinez, Purificacion
    Mori, Marta
    Falo, Catalina
    Antolin, Silvia
    Rodriguez, Cesar A.
    Margeli, Mireia
    Garau, Isabel
    Tibau, Ariadna
    Moreno, Diana
    Cruz, Josefina
    Echarri, M. Jose
    Lao, Juan
    Rodriguez-Lescure, Alvaro
    Jose Miralles, Juan
    Bezares, Susana
    Rojo, Federico
    Jara, Carlos
    CANCER RESEARCH, 2021, 81 (04)
12345